Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

12.06.2020 | review article | Ausgabe 3-4/2021

Wiener klinische Wochenschrift 3-4/2021

A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia

Wiener klinische Wochenschrift > Ausgabe 3-4/2021
Rahat Ullah, Junaid Wazir, Md Amir Hossain, Maladho Tanta Diallo, Farhan Ullah Khan, Awais Ullah Ihsan, Xiaohui Zhou
Wichtige Hinweise
The authors R. Ullah and J. Wazir contributed equally to the manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Benign prostatic hyperplasia (BPH) is a common disease that can cause uncomfortable lower urinary tract symptoms. The occurrence of symptomatic BPH develops after the age of 40 years and increases gradually with age to reach more than 50% at the age of 60 years and severely disturbs the quality of life of the patients. Alpha-blockers and 5‑alpha reductase inhibitors are first-line agents used for the treatment of BPH. Due to the adverse effects of these conventional therapies, many patients turn to phytotherapy and other alternative therapies. This review covers alternative therapies, i.e., phytotherapy (cernilton, eviprostat, quercetin, saw palmetto and pumpkin seed) and physical therapy (acupuncture, aquablation, pulsed electromagnetic field, prostate urethral lift, radial extracorporeal shock wave therapy, thermobalancing therapy, and transurethral needle ablation) commonly used in the management of BPH.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3-4/2021

Wiener klinische Wochenschrift 3-4/2021 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month